SOD1 — Superoxide Dismutase 1

SOD1 — Superoxide Dismutase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SOD1 — Superoxide Dismutase 1</th>
</tr>
<tr> [@pasinelli2010]
<td class="label">Symbol</td> [@redler2015]
<td><strong>SOD1</strong></td> [@girling2015]
</tr> [@schmittjohn2014]
<tr> [@miller2016]
<td class="label">Full Name</td> [@benatar2020]
<td>Superoxide Dismutase 1</td> [@abe2022]
</tr> [@whittaker2015]
<tr> [@ferraiuolo2011]
<td class="label">Chromosome</td> [@sathasivam2021]
<td>21q22.11</td> [@woehlbier2016]
</tr> [@frakes2014]
<tr> [@philips2015]
<td class="label">NCBI Gene</td> [@bendotti2012]
<td><a href="https://www.ncbi.nlm.nih.gov/gene/6647" target="_blank">6647</a></td> [@scekiczahirovic2016]
</tr> [@chia2023]
<tr> [@mcgoldrick2013]
<td class="label">Ensembl</td> [@lee2019]
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142168" target="_blank">ENSG00000142168</a></td> [@igoudjil2015]
</tr> [@matsumoto2015]
<tr> [@renton2014]
<td class="label">OMIM</td> [@tokuda2014]
<td><a href="https://omim.org/entry/147450" target="_blank">147450</a></td> [@chang2015]
</tr> [@liao2015]
<tr> [@lu2015]
<td class="label">UniProt</td> [@kak2014]
<td><a href="https://www.uniprot.org/uniprot/P00441" target="_blank">P00441</a></td> [@chen2016]
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Amyotrophic Lateral Sclerosis](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)</td>

SOD1 — Superoxide Dismutase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SOD1 — Superoxide Dismutase 1</th>
</tr>
<tr> [@pasinelli2010]
<td class="label">Symbol</td> [@redler2015]
<td><strong>SOD1</strong></td> [@girling2015]
</tr> [@schmittjohn2014]
<tr> [@miller2016]
<td class="label">Full Name</td> [@benatar2020]
<td>Superoxide Dismutase 1</td> [@abe2022]
</tr> [@whittaker2015]
<tr> [@ferraiuolo2011]
<td class="label">Chromosome</td> [@sathasivam2021]
<td>21q22.11</td> [@woehlbier2016]
</tr> [@frakes2014]
<tr> [@philips2015]
<td class="label">NCBI Gene</td> [@bendotti2012]
<td><a href="https://www.ncbi.nlm.nih.gov/gene/6647" target="_blank">6647</a></td> [@scekiczahirovic2016]
</tr> [@chia2023]
<tr> [@mcgoldrick2013]
<td class="label">Ensembl</td> [@lee2019]
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142168" target="_blank">ENSG00000142168</a></td> [@igoudjil2015]
</tr> [@matsumoto2015]
<tr> [@renton2014]
<td class="label">OMIM</td> [@tokuda2014]
<td><a href="https://omim.org/entry/147450" target="_blank">147450</a></td> [@chang2015]
</tr> [@liao2015]
<tr> [@lu2015]
<td class="label">UniProt</td> [@kak2014]
<td><a href="https://www.uniprot.org/uniprot/P00441" target="_blank">P00441</a></td> [@chen2016]
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Amyotrophic Lateral Sclerosis](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Motor cortex, Spinal cord, Widespread throughout CNS</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">A4V (most common in North America), D90A, G93A, G93C, H46R, I113T, L126Z, L84F</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1152 edges</a></td>
</tr>
</table>

SOD1 — Superoxide Dismutase 1

Overview

[SOD1](/genes/sod1) (Superoxide Dismutase 1) is a highly conserved metalloenzyme that catalyzes the dismutation of superoxide radical (O₂⁻) into hydrogen peroxide (H₂O₂) and molecular oxygen (O₂) [1](https://pubmed.ncbi.nlm.nih.gov/14749736/). The SOD1 gene is located on chromosome 21q22.11 and encodes a 154-amino acid protein with a molecular weight of approximately 15.7 kDa [2](https://pubmed.ncbi.nlm.nih.gov/14749736/). This enzyme is ubiquitously expressed throughout the central nervous system (CNS) and peripheral tissues, with particularly high expression in motor neurons of the spinal cord and cortical neurons [3](https://pubmed.ncbi.nlm.nih.govPMC2995682/). PMID: 32125907

The discovery that mutations in SOD1 cause familial amyotrophic lateral sclerosis (ALS) revolutionized our understanding of neurodegenerative disease mechanisms [4](https://pubmed.ncbi.nlm.nih.gov/8247589/). Since the initial identification of SOD1 mutations in ALS patients in 1993, over 200 pathogenic variants have been identified, making it one of the most common genetic causes of familial ALS [5](https://pubmed.ncbi.nlm.nih.gov/23576675/). Interestingly, while SOD1 is best known for its role in ALS, substantial evidence implicates SOD1 dysfunction in the pathogenesis of other major neurodegenerative disorders, including [Alzheimer's disease](/diseases/alzheimers-disease) [6](https://pubmed.ncbi.nlm.nih.gov/25919565/), [Parkinson's disease](/diseases/parkinsons-disease) [7](https://pubmed.ncbi.nlm.nih.gov/24866164/), and Huntington's disease [8](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/). PMID: 39366938

Structure and Biochemistry

Protein Structure

The SOD1 protein adopts a Greek key beta-barrel fold consisting of eight beta-strands arranged in a barrel-like structure [9](https://pubmed.ncbi.nlm.nih.gov/14749736/). Each monomer contains: PMID: 30010620

• Active site: Contains a copper ion (Cu) and a zinc ion (Zn) coordinated by specific amino acid residues
• Dimer interface: Two monomers form a stable homodimer, which is essential for enzymatic activity
• Disulfide bond: A conserved Cys57-Cys146 disulfide bond stabilizes the dimeric structure
• Copper chaperone binding site: Interfaces with the copper chaperone for SOD1 (CCS) for metal ion insertion PMID: 25492944

Enzymatic Mechanism

SOD1 catalyzes the dismutation of superoxide through a cyclic redox mechanism involving alternating reduction and oxidation of the copper ion at the active site [12](https://pubmed.ncbi.nlm.nih.gov/14749736/):

This catalytic cycle allows SOD1 to neutralize superoxide radicals at diffusion-limited rates, making it a critical component of cellular antioxidant defense [13](https://pubmed.ncbi.nlm.nih.gov/PMC2995682/).

Post-Translational Modifications

SOD1 undergoes several important post-translational modifications that modulate its function and stability:

• Copper chaperone-mediated copper insertion: The copper chaperone for SOD1 (CCS) facilitates copper incorporation and disulfide bond formation [14](https://pubmed.ncbi.nlm.nih.gov/PMC2995682/)
• Disulfide bond reduction: The disulfide bond can be reduced in response to cellular redox state, affecting protein stability
• Oxidation modifications: Oxidative stress can lead to oxidation of cysteine residues, methionine oxidation, and carbonyl formation [15](https://pubmed.ncbi.nlm.nih.gov/24866164/)
• Acetylation and phosphorylation: Various post-translational modifications have been detected in SOD1, though their functional significance is still being elucidated [16](https://pubmed.ncbi.nlm.nih.gov/25919565/)

Expression Pattern and Cellular Distribution

Central Nervous System Expression

SOD1 is expressed at high levels throughout the CNS, with particularly notable expression in:

• Motor neurons: Both upper motor neurons in the motor cortex and lower motor neurons in the spinal cord show high SOD1 expression, explaining the vulnerability of motor neurons in ALS [17](https://pubmed.ncbi.nlm.nih.gov/8247589/)
• Cortical neurons: Pyramidal neurons in all cortical layers express SOD1
• Substantia nigra: Dopaminergic neurons in the [substantia nigra pars compacta](/cell-types/substantia-nigra-pars-compacta-parkinsons) express SOD1, linking it to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis [18](https://pubmed.ncbi.nlm.nih.gov/24866164/)
• Astrocytes and microglia: Glial cells also express SOD1, contributing to overall CNS antioxidant defense [19](https://pubmed.ncbi.nlm.nih.gov/PMC2995682/)

Subcellular Localization

In neurons, SOD1 is primarily localized to the:

• Cytoplasm: The majority of SOD1 resides in the cytosol
• Mitochondria: A fraction of SOD1 is imported into mitochondria, particularly in neurons, where it provides protection against mitochondrial oxidative stress [20](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)
• Nucleus: SOD1 has been detected in the nucleus, where it may protect DNA from oxidative damage
• Axons and dendrites: Neuronal processes contain SOD1, where it may protect against oxidative damage during transport [21](https://pubmed.ncbi.nlm.nih.gov/PMC2995682/)

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

SOD1 mutations account for approximately 12-20% of familial ALS cases and about 1-2% of sporadic ALS cases [22](https://pubmed.ncbi.nlm.nih.gov/23576675/). Over 200 pathogenic mutations have been identified throughout the SOD1 gene, with varying frequencies across different populations:

| Mutation | Population | Frequency | Clinical Phenotype |
|----------|------------|-----------|-------------------|
| A4V | North America | ~50% of SOD1-ALS | Rapid progression |
| D90A | Scandinavia | Common | Slow progression |
| G93A | Global | Common | Intermediate progression |
| H46R | Japan | Common | Slow progression |
| I113T | Global | Rare | Variable |

The pathogenesis of SOD1-related ALS involves multiple interconnected mechanisms:

1. Toxic Gain of Function

Mutant SOD1 proteins acquire toxic properties that lead to neurodegeneration, independent of their enzymatic activity. Transgenic mice expressing mutant SOD1 develop ALS-like phenotypes even when the enzymatic activity is eliminated, demonstrating that the disease mechanism involves toxic gain of function [23](https://pubmed.ncbi.nlm.nih.gov/8247589/).

2. Protein Aggregation

Mutant SOD1 has a strong tendency to form insoluble aggregates that accumulate in the cytoplasm of motor neurons [24](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/). These aggregates:

• Disrupt proteasome function and autophagy
• Impair mitochondrial function
• Sequester essential cellular proteins
• Activate endoplasmic reticulum stress pathways

3. Mitochondrial Dysfunction

SOD1 mutants cause mitochondrial pathology through multiple mechanisms:

• Direct interaction with mitochondrial proteins
• Impaired mitochondrial trafficking
• Increased mitochondrial oxidative stress
• Disruption of mitochondrial membrane potential [25](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)

4. Excitotoxicity

SOD1 mutations may contribute to excitotoxic motor neuron death through:

• Dysregulation of glutamate transporter expression
• Impaired calcium homeostasis
• Increased sensitivity to glutamate-induced toxicity [26](https://pubmed.ncbi.nlm.nih.gov/8247589/)

5. Axonal Transport Defects

Mutant SOD1 disrupts axonal transport through:

• Direct interaction with transport proteins
• Impairment of mitochondrial transport
• Disruption of cytoskeletal integrity [27](https://pubmed.ncbi.nlm.nih.gov/PMC2995682/)

Alzheimer's Disease

While SOD1 mutations are not a primary cause of Alzheimer's disease, altered SOD1 function contributes to disease pathogenesis:

• Oxidative stress: Reduced SOD1 activity in AD brain correlates with increased oxidative damage [28](https://pubmed.ncbi.nlm.nih.gov/25919565/)
• Aβ interaction: Amyloid-beta (Aβ) peptides interact with SOD1, potentially inhibiting its activity and promoting aggregation [29](https://pubmed.ncbi.nlm.nih.gov/25919565/)
• Tau pathology: SOD1 dysfunction may contribute to tau phosphorylation and aggregation [30](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)

Parkinson's Disease

SOD1 plays a complex role in [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis:

• Oxidative stress: The substantia nigra of PD patients shows decreased SOD1 activity [31](https://pubmed.ncbi.nlm.nih.gov/24866164/)
• α-Synuclein interaction: SOD1 can interact with [alpha-synuclein](/proteins/alpha-synuclein) and modulate its aggregation [32](https://pubmed.ncbi.nlm.nih.gov/24866164/)
• Mitochondrial protection: SOD1 helps protect dopaminergic neurons from mitochondrial oxidative stress [33](https://pubmed.ncbi.nlm.nih.gov/24866164/)

Other Neurodegenerative Disorders

• Huntington's disease: SOD1 aggregation has been observed in HD models and patient tissue [34](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)
• Frontotemporal dementia: Some FTD cases show SOD1 pathology
• Spinocerebellar ataxias: SOD1 dysfunction may contribute to cerebellar degeneration

Therapeutic Approaches

Gene Silencing Strategies

RNA interference (RNAi) and antisense oligonucleotide (ASO) approaches target mutant SOD1 mRNA to reduce toxic protein expression:

• Antisense oligonucleotides: Multiple ASO candidates have entered clinical trials for SOD1-ALS [35](https://pubmed.ncbi.nlm.nih.gov/23576675/)
• RNAi-based approaches: Viral vector-delivered RNAi constructs show promise in preclinical models [36](https://pubmed.ncbi.nlm.nih.gov/23576675/)

Small Molecule Inhibitors

Several small molecule approaches target SOD1 aggregation:

• Argyrin analogues: Inhibit proteasome-induced SOD1 aggregation [37](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)
• Copper chelators: Modulate SOD1 metal content to reduce aggregation
• Aggregation inhibitors: Compounds that prevent SOD1 oligomerization and aggregation [38](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)

Protein Stabilization

• Disulfide bond stabilizers: Compounds that maintain the proper disulfide bond structure
• Pharmacological chaperones: Small molecules that bind to SOD1 and promote proper folding [39](https://pubmed.ncbi.nlm.nih.gov/23576675/)

Antioxidant Approaches

Given the role of oxidative stress in SOD1-related pathogenesis:

• SOD1 mimetics: Synthetic compounds that mimic SOD1 enzymatic activity
• General antioxidants: N-acetylcysteine, vitamin E, and coenzyme Q10 have been tested [40](https://pubmed.ncbi.nlm.nih.gov/PMC2995682/)

Clinical Trials

Several clinical trials have targeted SOD1 in ALS:

• Tofersen (BIIB067): Antisense oligonucleotide targeting SOD1 mRNA - completed Phase 1/2 and Phase 3 studies [41](https://pubmed.ncbi.nlm.nih.gov/23576675/)
• ASO strategies: Multiple companies developing next-generation ASOs
• Gene therapy approaches: AAV-delivered RNAi and ASO constructs in development [42](https://pubmed.ncbi.nlm.nih.gov/23576675/)

Animal Models

Transgenic Mouse Models

Multiple transgenic mouse models expressing human mutant SOD1 have been developed:

• SOD1-G93A: High copy number, rapid disease progression
• SOD1-G37R: Moderate progression
• SOD1-D90A: Slow progression, similar to human D90A-ALS
• SOD1-ALS models with conditional expression: Allow temporal control of mutant expression [43](https://pubmed.ncbi.nlm.nih.gov/8247589/)

Other Model Systems

• C. elegans: Simple model for studying SOD1 aggregation
• Zebrafish: Useful for developmental and behavioral studies
• Induced pluripotent stem cells (iPSCs): Patient-derived motor neurons for drug screening [44](https://pubmed.ncbi.nlm.nih.gov/23576675/)

Interaction Network

SOD1 interacts with numerous proteins involved in neurodegeneration:

• CCS (Copper chaperone for SOD1): Facilitates copper insertion and dimerization
• Bcl-2 family proteins: Modulate apoptosis in SOD1-ALS
• Proteasome subunits: Impaired by SOD1 aggregates
• Mitochondrial proteins: VDAC, Hsp60, other mitochondrial proteins
• Autophagy receptors: p62/SQSTM1, optineurin in ALS models [45](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)

Genetic Epidemiology

Population Frequencies

SOD1 mutations show significant population variability:

• European descent: D90A and G93A are the most common mutations
• North American: A4V accounts for approximately 50% of SOD1-ALS cases
• Asian populations: H46R is more prevalent in Japanese and Chinese cohorts
• Founder effects: Specific mutations show clustering in certain families and regions

Penetrance and Phenotype Variability

The penetrance of SOD1 mutations varies significantly:

• Age-dependent: Most SOD1-ALS cases develop symptoms between ages 40-70
• Incomplete penetrance: Some mutation carriers remain asymptomatic into late life
• Phenotype modifiers: Genetic modifiers influence age of onset and progression rate

Cellular Stress Pathways

Endoplasmic Reticulum Stress

Mutant SOD1 triggers ER stress through:

• Unfolded protein response (UPR): Activation of PERK, IRE1, and ATF6 pathways
• CHOP expression: Pro-apoptotic transcription factor upregulation
• Calcium dysregulation: ER calcium store depletion
• ER-associated degradation (ERAD): Impaired protein quality control [47](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)

Oxidative Stress

While wild-type SOD1 neutralizes superoxide, mutant SOD1 contributes to oxidative stress:

• Hydrogen peroxide accumulation: Altered enzymatic activity leads to H₂O₂ buildup
• Protein oxidation: Carbonyl formation on SOD1 and other proteins
• Lipid peroxidation: Membrane damage in motor neurons
• DNA oxidation: 8-OHdG accumulation in ALS tissue [48](https://pubmed.ncbi.nlm.nih.gov/PMC2995682/)

Inflammatory Responses

Neuroinflammation is a hallmark of SOD1-ALS:

• Microglial activation: Pro-inflammatory cytokine release
• Astrocytic reactivity: Altered support functions
• T-cell infiltration: Adaptive immune responses
• Cytokine profiles: TNF-α, IL-1β, IL-6 elevation [49](https://pubmed.ncbi.nlm.nih.gov/PMC2995682/)

Diagnostic Significance

Genetic Testing

SOD1 mutation testing is recommended for:

• Patients with familial ALS
• Young-onset sporadic ALS (<40 years)
• ALS patients with unusual clinical features
• Family history of neurodegenerative disease

Biomarkers

Several biomarkers are being studied for SOD1-ALS:

• Neurofilament light chain (NfL): Elevated in CSF and blood
• Neurofilament heavy chain (pNfH): Disease progression marker
• SOD1 activity: Decreased enzymatic function
• SOD1 aggregation: Detectable in patient tissue [50](https://pubmed.ncbi.nlm.nih.gov/23576675/)

Clinical Features

SOD1-ALS typically presents with:

• Classic ALS phenotype: Combined upper and lower motor neuron signs
• Limb onset: Most common presentation
• Relatively preserved cognition: Unlike some other genetic forms
• Variable progression: Depends on specific mutation

Comparative Biology

Species Conservation

SOD1 is highly conserved across species:

• Humans: 154 amino acids
• Mice: 154 amino acids, 84% identity
• Zebrafish: 155 amino acids, 70% identity
• C. elegans: 153 amino acids, 60% identity

Evolutionary Considerations

The high conservation suggests essential cellular functions:

• Ancient origin: Present in all aerobic organisms
• Essential enzyme: Knockout mice show increased oxidative damage
• Redox regulation: Critical for cellular homeostasis

Quality Control Mechanisms

Molecular Chaperones

Cells employ multiple chaperone systems:

• Hsp70 family: Prevents aggregation
• Hsp90: Involved in degradation pathways
• Small Hsp: Including Hsp27 and αB-crystallin
• J-domain proteins: Hsp40 family members [51](https://pubmed.ncbi.nlm.nih.gov/PMC4230356/)

Degradation Pathways

Mutant SOD1 is cleared by:

• Ubiquitin-proteasome system (UPS): Primary degradation pathway
• Autophagy-lysosome system: Macroautophagy and mitophagy
• ERAD: ER-associated degradation
• Aggresome-autophagy pathway: Sequestration and clearance

Future Directions

Emerging Therapies

Promising therapeutic approaches include:

• Gene editing: CRISPR-Cas9 approaches to correct mutations
• RNA targeting: Advanced ASO designs
• Protein-protein interaction inhibitors: Blocking toxic interactions
• Cell replacement therapies: Stem cell-based approaches [52](https://pubmed.ncbi.nlm.nih.gov/23576675/)

Research Priorities

Key areas for future investigation:

• Aggregation mechanisms: Detailed structural studies
• Toxic species identification: Which oligomers are most harmful
• Biomarker validation: Clinical utility studies
• Combination therapy design: Multi-target approaches

Conclusion

SOD1 represents a paradigm for understanding neurodegenerative disease mechanisms. From its essential role in cellular antioxidant defense to its pathological involvement in ALS and other disorders, SOD1 continues to be a focus of intense research. The development of therapeutic agents targeting SOD1, particularly antisense oligonucleotides, offers hope for patients with SOD1-ALS and may provide insights applicable to other neurodegenerative conditions. As our understanding of SOD1 biology deepens, new therapeutic opportunities will likely emerge, bringing us closer to effective treatments for these devastating diseases.

The SOD1 field has made remarkable progress since the initial discovery of ALS-causing mutations in 1993. Today, we have sophisticated animal models, detailed structural understanding, and multiple clinical trials targeting different aspects of SOD1 pathogenesis. The success of tofersen in clinical trials demonstrates that genetic targeting can provide clinical benefit, paving the way for future gene-specific therapies.

For researchers and clinicians working in the neurodegenerative disease field, SOD1 provides an important model system for understanding protein misfolding, aggregation, and cellular stress responses that are common to many neurological disorders. The knowledge gained from SOD1 research has direct relevance to Alzheimer's disease, Parkinson's disease, Huntington's disease, and other proteinopathies.

Future directions include developing more effective delivery methods for therapeutic agents, identifying biomarkers that can predict treatment response, and understanding why motor neurons are particularly vulnerable to SOD1 pathology. The integration of stem cell models, advanced imaging, and systems biology approaches promises to accelerate progress toward effective treatments for SOD1-related diseases and the broader spectrum of neurodegenerative conditions.

Research Directions

Current research focuses on:

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Motor Neuron Disease](/diseases/motor-neuron-disease)
• [Superoxide Dismutase](/proteins/sod1-protein-expanded)

External Links

• [Allen Brain Atlas: SOD1](https://human.brain-map.org/microarray/search/show?search_term=SOD1)

Structure

AlphaFold DB provides a full-length predicted structure for SOD1 (UniProt [P00441](https://www.uniprot.org/uniprotkb/P00441/entry), model v6) with mean pLDDT 97.94. View the model at [AlphaFold DB](https://alphafold.ebi.ac.uk/entry/P00441) or download the [PDB file](https://alphafold.ebi.ac.uk/files/AF-P00441-F1-model_v6.pdb).

Domain and region confidence from per-residue pLDDT:

• Residues 1-154 (full-length protein): mean pLDDT 97.9 (very high).

UniProt function annotation: Destroys radicals which are normally produced within the cells and which are toxic to biological systems (PubMed:24140062). Catalyzes the oxidation of hydrogen sulfide (H2S) to sulfate, playing an important role in detoxifying H2S and limiting the accumulation of reactive sulfur species (RSS) such as persulfides and polysulfides (PubMed:36630448).
Subcellular localization: Cytoplasm, Nucleus.
Curated disease associations include: Amyotrophic lateral sclerosis 1; Spastic tetraplegia and axial hypotonia, progressive.

References

Pathway Diagram

The following diagram shows key molecular relationships for sod1 based on knowledge graph edges:

Pathway Diagram

The following diagram shows the key molecular relationships involving SOD1 — Superoxide Dismutase 1 discovered through SciDEX knowledge graph analysis:

Associated Diseases

• Als — associated with

• ALS — associated with

• Alzheimer — associated with

• ALZHEIMER — associated with

• Alzheimer's disease — associated with

• Alzheimer's Disease — biomarker for

• Alzheimer'S Disease — biomarker for

• amyotrophic lateral sclerosis — causes

• Amyotrophic Lateral Sclerosis — associated with

• dementia — associated with

• Dementia — associated with

• DEMENTIA — associated with

• FALS — causes

• Familial ALS — risk factor for

• Familial Amyotrophic Lateral Sclerosis — risk factor for

• frontotemporal — associated with

• frontotemporal dementia — associated with

• Frontotemporal Dementia — causes

• FRONTOTEMPORAL DEMENTIA — associated with

• Parkinson — associated with

• PARKINSON — associated with

• Parkinson's disease — associated with

• SALS — associated with